The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor
Open accessAbstract
DFU (5,5‐dimethyl‐3‐(3‐fluorophenyl)‐4‐(4‐methylsulphonyl)phenyl‐2(5H)‐furanone) was identified as a novel orally active and highly selective cyclo‐oxygenase‐2 (COX‐2) inhibitor. In CHO cells stably transfected with human COX isozymes, DFU inhibited the arachidonic acid‐dependent production of prostaglandin E 2 (PGE 2) with at least a 1,000 fold selectivity for COX‐2 (IC 50=41±14 n M) over COX‐1 (IC 50>50 μ M). Indomethacin was a potent inhibitor of both COX‐1 (IC 50=18±3 n M) and COX‐2 (IC 50=26±6 n M) under the same assay conditions. The large increase in selectivity of DFU over indomethacin was also observed in COX‐1 mediated production of thromboxane B 2 (TXB 2) by Ca 2+ ionophore‐challenged human platelets (IC 50>50 μ M and 4.1±1.7 n M, respectively). DFU caused a time‐dependent inhibition of purified recombinant human COX‐2 with a Ki value of 140±68 μ M for the initial reversible binding to enzyme and a k2 value of 0.11±0.06 s−1 for the first order rate constant for formation of a tightly bound enzyme‐inhibitor complex. Comparable values of 62±26 μ M and 0.06±0.01 s−1, respectively, were obtained for indomethacin. The enzyme‐inhibitor complex was found to have a 1 : 1 stoichiometry and to dissociate only very slowly (t1/2=1–3 h) with recovery of intact inhibitor and active enzyme. The time‐dependent inhibition by DFU was decreased by co‐incubation with arachidonic acid under non‐turnover conditions, consistent with reversible competitive inhibition at the COX active site. Inhibition of purified recombinant human COX‐1 by DFU was very weak and observed only at low concentrations of substrate (IC 50=63±5 μ M at 0.1 μ M arachidonic acid). In contrast to COX‐2, inhibition was time‐independent and rapidly reversible. These data are consistent with a reversible competitive inhibition of COX‐1. DFU inhibited lipopolysaccharide (LPS)‐induced PGE 2 production (COX‐2) in a human whole blood assay with a potency (IC 50=0.28±0.04 μ M) similar to indomethacin (IC 50=0.68±0.17 μ M). In contrast, DFU was at least 500 times less potent (IC 50>97 μ M) than indomethacin at inhibiting coagulation‐induced TXB 2 production (COX‐1) (IC 50=0.19±0.02 μ M). In a sensitive assay with U937 cell microsomes at a low arachidonic acid concentration (0.1 μ M), DFU inhibited COX‐1 with an IC 50 value of 13±2 μ M as compared to 20±1 n M for indomethacin. CGP 28238, etodolac and SC‐58125 were about 10 times more potent inhibitors of COX‐1 than DFU. The order of potency of various inhibitors was diclofenac>indomethacin∼naproxen>nimesulide∼ meloxicam∼piroxicam>NS‐398∼SC‐57666>SC‐58125>CGP 28238∼etodolac>L‐745,337>DFU. DFU inhibited dose‐dependently both the carrageenan‐induced rat paw oedema (ED 50 of 1.1 mg kg−1 vs 2.0 mg kg−1 for indomethacin) and hyperalgesia (ED 50 of 0.95 mg kg−1 vs 1.5 mg kg−1 for indomethacin). The compound was also effective at reversing LPS‐induced pyrexia in rats (ED 50=0.76 mg kg−1 vs 1.1 mg kg−1 for indomethacin). In a sensitive model in which 51 Cr faecal excretion was used to assess the integrity of the gastrointestinal tract in rats, no significant effect was detected after oral administration of DFU (100 mg kg−1, b.i.d.) for 5 days, whereas chromium leakage was observed with lower doses of diclofenac (3 mg kg−1), meloxicam (3 mg kg−1) or etodolac (10–30 mg kg−1). A 5 day administration of DFU in squirrel monkeys (100 mg kg−1) did not affect chromium leakage in contrast to diclofenac (1 mg kg−1) or naproxen (5 mg kg−1). The results indicate that COX‐1 inhibitory effects can be detected for all selective COX‐2 inhibitors tested by use of a sensitive assay at low substrate concentration. The novel inhibitor DFU shows the lowest inhibitory potency against COX‐1, a consistent high selectivity of inhibition of COX‐2 over COX‐1 (>300 fold) with enzyme, whole cell and whole blood assays, with no detectable loss of integrity of the gastrointestinal tract at doses >200 fold higher than efficacious doses in models of inflammation, pyresis and hyperalgesia. These results provide further evidence that prostanoids derived from COX‐1 activity are not important in acute inflammatory responses and that a high therapeutic index of anti‐inflammatory effect to gastropathy can be achieved with a selective COX‐2 inhibitor. British Journal of Pharmacology (1997) 121, 105–117; doi:10.1038/sj.bjp.0701076
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., & Isakson, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12013 · Cited by 1,551
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310 · cited 1×
“COX-1 is the major COX isozyme present in the gastrointestinal tract of many species (Kargman et al., 1996a) and ulcerogenic sparing selective COX-2 inhibitors do not inhibit stomach PGE2 production in contrast to nonselective NSAIDs (Futaki et al., 1993a; Masferrer et al., 1994; Chan et al., 1995).”
BackgroundHerschman, H. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00194-8 · Cited by 1,197
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., Kluckman, K. D., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90126-4 · Cited by 1,123
Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs
Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., & Russell, R. I. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209103271101 · Cited by 958
Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., & Breyer, M. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117620 · Cited by 860
New insights into the mode of action of anti-inflammatory drugs
Vane, J. R., & Botting, R. M. (1995) · Inflammation Research · doi:10.1007/bf01630479 · Cited by 838
Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., & Otomo, S. (1994) · Prostaglandins · doi:10.1016/0090-6980(94)90074-4 · Cited by 826
Funk, C. D., Funk, L. B., Kennedy, M. E., Pong, A. S., & Fitzgerald, G. A. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.9.1907252 · Cited by 571
Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., & O'Neill, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690211 · Cited by 462
Self-citationMechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.
Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S., & Trzaskos, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11202 · Cited by 408
Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H., & Otomo, S. (1993) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(93)90018-s · Cited by 344
Engelhardt, G., Homma, D., Schlegel, K., Utzmann, R., & Schnitzler, C. (1995) · Inflammation Research · doi:10.1007/bf01757699 · Cited by 333
Chan, C. C., Boyce, S., Brideau, C., Ford-Hutchinson, A. W., Gordon, R., Guay, D., Hill, R. G., Li, C. S., Mancini, J., & Penneton, M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10713-1 · Cited by 313
Self-citationRenal Toxicity of the Nonsteroidal Anti-Inflammatory Drugs
Murray, M. D., & Brater, D. C. (1993) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.002251 · Cited by 294
Rome, L. H., & Lands, W. E. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.4863 · Cited by 290
Brideau, C., Kargman, S., Liu, S., Dallob, A. L., Ehrich, E. W., Rodger, I. W., & Chan, C. C. (1996) · Inflammation Research · doi:10.1007/bf02265118 · Cited by 279
Self-citationGriswold, D. E., & Adams, J. L. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199603)16:2<181::aid-med3>3.0.co;2-x · Cited by 253
Gans, K. R., Galbraith, W., Roman, R. J., Haber, S. B., Kerr, J. S., Schmidt, W. K., Smith, C., Hewes, W. E., & Ackerman, N. R. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12610-4 · Cited by 231
Meloxican: Influence on arachidonic acid metabolism
Engelhardt, G., Bögel, R., Schnitzler, C., & Utzmann, R. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02110-8 · Cited by 218
Selective inhibition of cyclooxygenase 2
Klein, T., Nüsing, R. M., Pfeilschifter, J., & Ullrich, V. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90205-4 · Cited by 180
Noble, S., & Balfour, J. A. (1996) · Drugs · doi:10.2165/00003495-199651030-00007 · Cited by 165
Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms
Ouellet, M., & Percival, M. D. (1995) · Biochemical Journal · doi:10.1042/bj3060247 · Cited by 154
Self-citationFutaki, N., Arai, I., Hamasaka, Y., Takahashi, S., Higuchi, S., & Otomo, S. (1993) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1993.tb07103.x · Cited by 154
Meloxican: Influence on arachidonic acid metabolism
Engelhardt, G., Bögel, R., Schnitzer, C., & Utzmann, R. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02111-6 · Cited by 149
Reitz, D. B., Li, J. J., Norton, M. B., Reinhard, E. J., Collins, J. T., Anderson, G. D., Gregory, S. A., Koboldt, C. M., & Perkins, W. E. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00049a005 · Cited by 118
Novel Terphenyls as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents
Li, J. J., Norton, M. B., Reinhard, E. J., Anderson, G. D., Gregory, S. A., Isakson, P. C., Koboldt, C. M., Masferrer, J. L., Perkins, W. E., Seibert, K., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950878e · Cited by 109
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
Kargman, S., Wong, E., Greig, G. M., Falgueyret, J., Cromlish, W. A., Ethier, D., Yergey, J. A., Riendeau, D., Evans, J. F., Kennedy, B. P., et al. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00462-5 · Cited by 104
Self-citationActivity of nimesulide on constitutive and inducible cyclooxygenases.
TAVARES, I. A., Bishai, P. M., & Bennett, A. B. (1995) · PubMed · Cited by 98
Young, J. M., Panah, S., Satchawatcharaphong, C., & Cheung, P. S. (1996) · Inflammation Research · doi:10.1007/bf02259611 · Cited by 97
Role of prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy
Harada, Y., Hatanaka, K., Kawamura, M., Saito, M., Ogino, M., Majima, M., Ohno, T., Ogino, K., Yamamoto, K., Taketani, Y., et al. (1996) · Prostaglandins · doi:10.1016/0090-6980(95)00168-9 · Cited by 87
Callan, O., So, O., & Swinney, D. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3548 · Cited by 86
Wallace, J. L. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-215 · Cited by 84
Purification and Characterization of Recombinant Human Cyclooxygenase-2
Percival, M. D., Ouellet, M., Vincent, C. J., Yergey, J. A., Kennedy, B. P., & O’Neill, G. P. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1478 · Cited by 77
Self-citationClarke, G. D., MacPherson, I. S., Petrone, G., & Spangler, R. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90700-5 · Cited by 17
Cited by
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
COX-2 is expressed in human pulmonary, colonic, and mammary tumors
Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J., & Koki, A. T. (2000) · Cancer · doi:10.1002/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b · Cited by 862
Metadata
- Authors
- Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueyret, J. ‐., Ford‐Hutchinson, A. W., Gordon, R., Greig, G., Gresser, M., Guay, J., Kargman, S., Léger, S., Mancini, J. A., O'Neill, G., Ouellet, M., Rodger, I. W., Thérien, M., Wang, Z., Webb, J. K., Wong, E., Xu, L., Young, R. N., Zamboni, R., Prasit, P., & Chan, C. ‐.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1997-05
- Volume
- 121
- Issue
- 1
- Pages
- 105-117
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2024608254
- Cited by
- 322
- References
- 35
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.